

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 86358/JND/CH	FOR FURTHER ACTION <small>see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.</small>	
International application No. PCT/GB 98/ 00130	International filing date (day/month/year) 15/01/1998	(Earliest) Priority Date (day/month/year) 15/01/1997
Applicant BRAX GENOMICS LIMITED et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. ☐ Certain claims were found unsearchable (see Box I).

2. ☐ Unity of invention is lacking (see Box II).

3. ☐ The international application contains disclosure of a **nucleotide and/or amino acid sequence listing** and the international search was carried out on the basis of the sequence listing

☐ filed with the international application.

☐ furnished by the applicant separately from the international application.

☐ but not accompanied by a statement to the effect that it did not include matter going beyond the disclosure in the international application as filed.

☐ Transcribed by this Authority

4. With regard to the title, ☒ the text is approved as submitted by the applicant

☐ the text has been established by this Authority to read as follows:

5. With regard to the abstract,

☒ the text is approved as submitted by the applicant

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this International Search Report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is:

Figure No. 1a ☐ as suggested by the applicant.

☐ None of the figures.

☒ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

INTERNATIONAL SEARCH REPORT

International Application No

PC 98/00130

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 04160 A (ISIS INNOVATION ; SOUTHERN EDWIN (GB); CUMMINS WILLIAM JONATHAN (GB)) 9 February 1995 see the whole document ---	1-20
X	WO 95 20053 A (MEDICAL RES COUNCIL ; SIBSON DAVID ROSS (GB)) 27 July 1995 cited in the application see page 23 - page 27; claims 9-13, 24-26, 28, 29; figure 2; examples 3, 4 ---	1-5, 7-11, 13-16, 18, 20
X	WO 96 33205 A (SPECTRAGEN INC) 24 October 1996 cited in the application see the whole document ---	1-5, 7-11, 13-16, 18, 20

-/-

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

8 May 1998

Date of mailing of the international search report

18/05/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Molina Galan, E

INTERNATIONAL SEARCH REPORT

International Application No

PCT/AB 98/00130

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 09248 A (ARCH DEV CORP ;DRMANAC RADOJE (US)) 6 April 1995 -----	
A	WO 89 11211 A (BIOTECHNOLOG FORSCHUNG GMBH) 30 November 1989 -----	

INTERNATIONAL SEARCH REPORT

International Application No

P S 94/10945

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GENOMICS, vol.13, no.4, August 1992, ACADEMIC PRESS, NEW YORK, US; pages 1378 - 1383 C.R. CANTOR ET AL. 'Report on the sequencing by hybridization workshop' cited in the application	1
Y	see page 1379, left column, line 10 - line 26; figure 1 ---	2-46
Y	SCIENCE, vol.258, no.5089, 11 December 1992, AAAS, WASHINGTON, DC, US; pages 1787 - 1791 J. KIELECZAWA ET AL. 'DNA sequencing by primer walking with strings of contiguous hexamers' see page 1787, middle column, line 5 - line 16 ---	2-46
Y	GENE, vol.90, no.1, 31 May 1990, ELSEVIER PUBLISHERS, N.Y., U.S.; pages 177 - 178 W. SZYBALSKI 'Proposal for sequencing DNA using ligation of hexamers to generate sequential elongation primers (SPEL-6)' the whole document ---	2-46
Y	WO,A,93 05183 (BAYLOR COLLEGE OF MEDICINE) 18 March 1993 see page 6, line 7 - page 12, line 18; claims 1-26; figure 4 ---	2-46
Y	WO,A,91 06678 (SRI INTERNATIONAL) 16 May 1991 see page 10, line 19 - page 18, line 33; claims 1-50; figure 1 ---	2-46
A	SCIENCE, vol.260, 11 June 1993, AAAS, WASHINGTON, DC, US; pages 1649 - 1652 R. DRMANAC ET AL. 'DNA sequence determination by hybridization: A strategy for efficient large-scale sequencing' the whole document ---	1-46
A	US,A,5 202 231 (DRMANAC ET AL.) 13 April 1993 cited in the application the whole document ---	1-46

	--- --	

1

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 94/10945

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>PROC. NATL. ACAD SCI., vol.86, September 1989, NATL. ACAD SCI., WASHINGTON, DC, US; pages 6917 - 6921 F.W. STUDIER 'A strategy for high-volume sequencing of cosmid DNAs: Random and directed priming with a library of oligonucleotides' the whole document ---</p>	1-46
A	<p>FEBS LETT., vol.256, no.1,2, October 1989, ELSEVIER PUBLISHERS, AMSTERDAM, NL; pages 118 - 122 K.R. KHRAPKO ET AL. 'An oligonucleotide hybridization approach to DNA sequencing' the whole document -----</p>	1-46

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/00130

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9504160 A	09-02-95	AT 159767 T	15-11-97
		AU 7269194 A	28-02-95
		CA 2168010 A	09-02-95
		CN 1131440 A	18-09-96
		DE 69406544 D	04-12-97
		DE 69406544 T	26-02-98
		EP 0711362 A	15-05-96
		EP 0778280 A	11-06-97
		ES 2108479 T	16-12-97
		FI 960403 A	29-01-96
		HU 73802 A	30-09-96
		JP 9501830 T	25-02-97
		NO 960370 A	28-03-96
WO 9520053 A	27-07-95	AU 1459595 A	08-08-95
		EP 0739422 A	30-10-96
		JP 9508268 T	26-08-97
WO 9633205 A	24-10-96	AU 5549096 A	07-11-96
WO 9509248 A	06-04-95	AU 8072794 A	18-04-95
		BR 9407712 A	12-02-97
		CA 2172722 A	06-04-95
		CN 1136330 A	20-11-96
		CZ 9600905 A	16-10-96
		EP 0723598 A	31-07-96
		FI 961283 A	22-05-96
		HU 75993 A	28-05-97
		JP 9505729 T	10-06-97
		NO 961165 A	23-05-96
		NZ 275194 A	22-09-97
		PL 313735 A	22-07-96
WO 8911211 A	30-11-89	DE 58908694 D	12-01-95
		EP 0377015 A	11-07-90
		JP 3502641 T	20-06-91
		US 5114839 A	19-05-92

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

P S 94/10945

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9305183	18-03-93	AU-A- 2674092	05-04-93
WO-A-9106678	16-05-91	EP-A- 0450060	09-10-91
US-A-5202231	13-04-93	NONE	

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

DANIELS, Jeffrey, Nicholas
Page White & Farrer
54 Doughty Street
London WC1N 2LS
ROYAUME-UNIRECEIVED
19 MAY 1999

Date of mailing (day/month/year) 04 May 1999 (04.05.99)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference 86358/JND/CH	
International application No. PCT/GB98/00130	International filing date (day/month/year) 15 January 1998 (15.01.98)

1. The following indications appeared on record concerning:		
<input checked="" type="checkbox"/> the applicant	<input type="checkbox"/> the inventor	<input type="checkbox"/> the agent
<input type="checkbox"/> the common representative		
Name and Address BRAX GENOMICS LIMITED 13 Station Road Cambridge CB1 2JB United Kingdom	State of Nationality GB	State of Residence GB
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	
2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:		
<input type="checkbox"/> the person	<input checked="" type="checkbox"/> the name	<input type="checkbox"/> the address
<input type="checkbox"/> the nationality		
<input type="checkbox"/> the residence		
Name and Address BRAX GROUP LIMITED 13 Station Road Cambridge CB1 2JB United Kingdom	State of Nationality GB	State of Residence GB
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	
3. Further observations, if necessary:		
4. A copy of this notification has been sent to:		
<input checked="" type="checkbox"/> the receiving Office	<input type="checkbox"/> the designated Offices concerned	
<input type="checkbox"/> the International Searching Authority	<input checked="" type="checkbox"/> the elected Offices concerned	
<input checked="" type="checkbox"/> the International Preliminary Examining Authority	<input type="checkbox"/> other:	

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Eugénia Santos Telephone No.: (41-22) 338.85.38
---	--

PATENT COOPERATION TREATY

PCT

From the INTERNATIONAL BUREAU

NOTIFICATION OF THE RECORDING OF A CHANGE

(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

To:

DANIELS, Jeffrey, Nicholas
Page White & Farrer
54 Doughty Street
London WC1N 2LS
ROYAUME-UNI

Date of mailing (day/month/year) 04 May 1999 (04.05.99)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference 86358/JND/CH	
International application No. PCT/GB98/00130	International filing date (day/month/year) 15 January 1998 (15.01.98)

1. The following indications appeared on record concerning:		
<input checked="" type="checkbox"/> the applicant	<input type="checkbox"/> the inventor	<input type="checkbox"/> the agent <input type="checkbox"/> the common representative
Name and Address BRAX GENOMICS LIMITED 13 Station Road Cambridge CB1 2JB United Kingdom	State of Nationality GB	State of Residence GB
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	
2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:		
<input type="checkbox"/> the person	<input checked="" type="checkbox"/> the name	<input type="checkbox"/> the address <input type="checkbox"/> the nationality <input type="checkbox"/> the residence
Name and Address BRAX GROUP LIMITED 13 Station Road Cambridge CB1 2JB United Kingdom	State of Nationality GB	State of Residence GB
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	
3. Further observations, if necessary:		
4. A copy of this notification has been sent to:		
<input checked="" type="checkbox"/> the receiving Office	<input type="checkbox"/> the designated Offices concerned	
<input type="checkbox"/> the International Searching Authority	<input checked="" type="checkbox"/> the elected Offices concerned	
<input checked="" type="checkbox"/> the International Preliminary Examining Authority	<input type="checkbox"/> other:	

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Eugénia Santos
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

United States Patent and Trademark
Office
(Box PCT)
Crystal Plaza 2
Washington, DC 20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 02 September 1998 (02.09.98)	
International application No. PCT/GB98/00130	Applicant's or agent's file reference 86358/JND/CH
International filing date (day/month/year) 15 January 1998 (15.01.98)	Priority date (day/month/year) 15 January 1997 (15.01.97)
Applicant SCHMIDT, Gunter et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:
14 August 1998 (14.08.98)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Eugénia Santos Telephone No.: (41-22) 338.83.38
---	--

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 86358/JND/CH	<div style="display: flex; justify-content: space-between;"> <div> FOR FURTHER ACTION </div> <div> <small>See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)</small> </div> </div>	
International application No. PCT/GB98/00130	International filing date (day/month/year) 15/01/1998	Priority date (day/month/year) 15/01/1997
International Patent Classification (IPC) or national classification and IPC C12Q1/68		
Applicant BRAX GENOMICS LIMITED et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 6 sheets, including this cover sheet.

☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 1 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☒ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand 14/08/1998	Date of completion of this report <div style="text-align: center; font-size: 1.2em;">12. 05. 1999</div>
Name and mailing address of the international preliminary examining authority: <div style="display: flex; align-items: center;"> <div> European Patent Office - P.B. 5818 Patentaan 2 NL-2280 HV Rijswijk - Pays Bas Tel. (+31-70) 340-2040 Tx: 31 651 epo nl Fax: (+31-70) 340-3016 </div> </div>	Authorized officer Molina Galan, E Telephone No. (+31-70)-340



**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/GB98/00130

I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

Description, pages:

1-34 as originally filed

Claims, No.:

2 (part), 3-20 as originally filed

1, 2 (part) as received on 26/02/1999 with letter of 23/02/1999

Drawings, sheets:

1/9-9/9 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

3. ☒ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

see separate sheet

4. Additional observations, if necessary:

see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/GB98/00130

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	1-12
	No:	Claims	13-20
Inventive step (IS)	Yes:	Claims	
	No:	Claims	1-20
Industrial applicability (IA)	Yes:	Claims	1-20
	No:	Claims	

2. Citations and explanations

see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GB98/00130

I. Basis (Continuation)

- 3.1 No basis for the wording "plurality" nor "in the same reaction zone" as such introduced in claim 1 could be found in the application as filed.
- 4.1 The following equivalent wording can however be construed from page 7: "... obtaining a target population comprising an *heterogeneous sub-population of non-spatially resolved* single stranded DNAs to be sequenced, ...".
- 4.2 For reasons of expediency, the IPEA has interpreted the wording mentioned in I.3.1, above as equivalent and in the sense of the wording given in I.4.1 and this IPER is established accordingly.

V. Reasoned statement (Continuation)

2.1 CITATIONS

Reference is made to the following documents:

- D1: WO-A-95/04160, Isis Innovation Ltd.
D2: US-A-512 42 47, EMBL

D2 is cited by the IPEA.

2.2 NOVELTY (Art. 33(2) PCT)

- 2.2.1 D1 discloses a method for sequencing DNA in which a target is hybridised with a library of probes bearing a mass label, the label is released from the probe to identify its sequence and a further probe is ligated to proceed establishing the target sequence (cf claims).

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GB98/00130

2.2.2 The present application does not satisfy the criterion set forth in Article 33(2) PCT because the subject-matter of claims 13-20 is not new in respect of prior art as defined in the regulations (Rule 64(1)-(3) PCT).

2.3 INVENTIVE STEP (Art. 33(3) PCT)

2.3.1 Document D1 is considered to represent the most relevant state of the art and has been discussed above. The subject-matter of claim 1 differs in that the heterogeneous sub-population of DNAs to be sequenced are not spatially resolved and each different DNA is present in a unique amount.

2.3.2 The problem to be solved by the subject matter of claim 1 may therefore be regarded as improving the method of D1 by dispensing with the need of spatially resolving each different DNA to be sequenced. The solution would be the provision of each different DNA in a unique amount so that the quantity of the label detected is an indication of the particular DNA generating said signal.

2.3.3 This solution cannot however be considered as involving an inventive step (Article 33(3) PCT) for the following reasons:

2.3.3.1 D2 discloses a method for sequencing nucleic acids by the dideoxy termination method in which the termination products for all four nucleotides are separated in the same lane (i.e. they are not spatially resolved) and the signal recorded at each length position is related with the given nucleotide by the signal intensity which is directly proportional to the unique concentration (i.e. amount) of the dideoxynucleotides present (cf claims).

2.3.3.2 The person skilled in the art would consider the teachings of D2 to improve the method of D1 and therefore claim 1 lacks an inventive step.

2.3.4 Dependent claims 2-12 do not appear to contain any additional features which, in combination with the features of any claim to which they refer, involve an inventive step because their technical features are present in D1.

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GB98/00130

- 2.3.5 The present application does therefore not satisfy the criterion set forth in Article 33(3) PCT and the subject-matter of claims 1-12 does not involve an inventive step (Rule 65(1)(2) PCT).

VII. Certain defects (Continuation)

- 1 Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in documents D1 and D2 is not mentioned in the description, nor are these documents identified therein.

CLAIMS:

1. A method for sequencing DNA, which comprises:

(a) obtaining a target DNA population comprising a plurality of single-stranded DNAs to be sequenced, each of which is present in a unique amount in the same reaction zone and bears a primer to provide a double-stranded portion of the DNA for ligation thereto;

(b) contacting the DNA population with an array of hybridisation probes, each probe comprising a label cleavably attached to a known base sequence of predetermined length, the array containing all possible base sequences of that predetermined length and the base sequences being incapable of ligation to each other, wherein the contacting is carried out in the presence of ligase under conditions to ligate to the double-stranded portion of each DNA the probe bearing the base sequence complementary to the single-stranded DNA adjacent the double-stranded portion thereby to form an extended double-stranded portion which is incapable of ligation to further probes; and

(c) removing all unligated probes; followed by the steps of:

(d) cleaving the ligated probes to release each label;

(e) recording the quantity of each label; and

(f) activating the extended double-stranded portion to enable ligation thereto; wherein

(g) steps (b) to (f) are repeated in a cycle for a sufficient number of times to determine the sequence of each single-stranded DNA by determining the sequence of release of each label.

2. A method according to claim 1, wherein the array comprises a plurality of sub-arrays which together contain all the possible

CLAIMS:

1. A method for sequencing DNA, which comprises:

(a) obtaining a target DNA population comprising one or more single-stranded DNAs to be sequenced, each of which is present in a unique amount and bears a primer to provide a double-stranded portion of the DNA for ligation thereto;

(b) contacting the DNA population with an array of hybridisation probes, each probe comprising a label cleavably attached to a known base sequence of predetermined length, the array containing all possible base sequences of that predetermined length and the base sequences being incapable of ligation to each other, wherein the contacting is carried out in the presence of ligase under conditions to ligate to the double-stranded portion of each DNA the probe bearing the base sequence complementary to the single-stranded DNA adjacent the double-stranded portion thereby to form an extended double-stranded portion which is incapable of ligation to further probes; and

(c) removing all unligated probes; followed by the steps of:

(d) cleaving the ligated probes to release each label;

(e) recording the quantity of each label; and

(f) activating the extended double-stranded portion to enable ligation thereto; wherein

(g) steps (b) to (f) are repeated in a cycle for a sufficient number of times to determine the sequence of the or each single-stranded DNA by determining the sequence of release of each label.

2. A method according to claim 1, wherein the array comprises a plurality of sub-arrays which together contain all the possible

PATENT COOPERATION TREATY

PCT

REC'D 18 MAY 1999

WIPO PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 86358/JND/CH	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/GB98/00130	International filing date (day/month/year) 15/01/1998	Priority date (day/month/year) 15/01/1997
International Patent Classification (IPC) or national classification and IPC C12Q1/68		
Applicant BRAX GENOMICS LIMITED et al.		



1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 6 sheets, including this cover sheet.

☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

 These annexes consist of a total of 1 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☒ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand 14/08/1998	Date of completion of this report 12 05 1999
Name and mailing address of the international preliminary examining authority:  European Patent Office - P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk - Pays Bas Tel. (+31-70) 340-2040 Tx: 31 651 epo nl Fax: (+31-70) 340-3016	Authorized officer Molina Galan, E Telephone No. (+31-70)-340 

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/GB98/00130

I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

Description, pages:

1-34 as originally filed

Claims, No.:

2 (part), 3-20 as originally filed

1, 2 (part) as received on 26/02/1999 with letter of 23/02/1999

Drawings, sheets:

1/9-9/9 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

3. ☒ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

see separate sheet

4. Additional observations, if necessary:

see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/GB98/00130

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	1-12
	No:	Claims	13-20
Inventive step (IS)	Yes:	Claims	
	No:	Claims	1-20
Industrial applicability (IA)	Yes:	Claims	1-20
	No:	Claims	

2. Citations and explanations

see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GB98/00130

I. Basis (Continuation)

- 3.1 No basis for the wording "plurality" nor "in the same reaction zone" as such introduced in claim 1 could be found in the application as filed.
- 4.1 The following equivalent wording can however be construed from page 7: "... obtaining a target population comprising an *heterogeneous sub-population of non-spatially resolved* single stranded DNAs to be sequenced, ...".
- 4.2 For reasons of expediency, the IPEA has interpreted the wording mentioned in I.3.1, above as equivalent and in the sense of the wording given in I.4.1 and this IPER is established accordingly.

V. Reasoned statement (Continuation)

2.1 CITATIONS

Reference is made to the following documents:

- D1: WO-A-95/04160, Isis Innovation Ltd.
D2: US-A-512 42 47, EMBL

D2 is cited by the IPEA.

2.2 NOVELTY (Art. 33(2) PCT)

- 2.2.1 D1 discloses a method for sequencing DNA in which a target is hybridised with a library of probes bearing a mass label, the label is released from the probe to identify its sequence and a further probe is ligated to proceed establishing the target sequence (cf claims).

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GB98/00130

2.2.2 The present application does not satisfy the criterion set forth in Article 33(2) PCT because the subject-matter of claims 13-20 is not new in respect of prior art as defined in the regulations (Rule 64(1)-(3) PCT).

2.3 INVENTIVE STEP (Art. 33(3) PCT)

2.3.1 Document D1 is considered to represent the most relevant state of the art and has been discussed above. The subject-matter of claim 1 differs in that the heterogeneous sub-population of DNAs to be sequenced are not spatially resolved and each different DNA is present in a unique amount.

2.3.2 The problem to be solved by the subject matter of claim 1 may therefore be regarded as improving the method of D1 by dispensing with the need of spatially resolving each different DNA to be sequenced. The solution would be the provision of each different DNA in a unique amount so that the quantity of the label detected is an indication of the particular DNA generating said signal.

2.3.3 This solution cannot however be considered as involving an inventive step (Article 33(3) PCT) for the following reasons:

2.3.3.1 D2 discloses a method for sequencing nucleic acids by the dideoxy termination method in which the termination products for all four nucleotides are separated in the same lane (i.e. they are not spatially resolved) and the signal recorded at each length position is related with the given nucleotide by the signal intensity which is directly proportional to the unique concentration (i.e. amount) of the dideoxynucleotides present (cf claims).

2.3.3.2 The person skilled in the art would consider the teachings of D2 to improve the method of D1 and therefore claim 1 lacks an inventive step.

2.3.4 Dependent claims 2-12 do not appear to contain any additional features which, in combination with the features of any claim to which they refer, involve an inventive step because their technical features are present in D1.

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GB98/00130

- 2.3.5 The present application does therefore not satisfy the criterion set forth in Article 33(3) PCT and the subject-matter of claims 1-12 does not involve an inventive step (Rule 65(1)(2) PCT).

VII. Certain defects (Continuation)

- 1 Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in documents D1 and D2 is not mentioned in the description, nor are these documents identified therein.




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/68	A1	(11) International Publication Number: WO 98/31831 (43) International Publication Date: 23 July 1998 (23.07.98)
<p>(21) International Application Number: PCT/GB98/00130</p> <p>(22) International Filing Date: 15 January 1998 (15.01.98)</p> <p>(30) Priority Data: 9700760.3 15 January 1997 (15.01.97) GB</p> <p>(71) Applicant (for all designated States except US): BRAX GENOMICS LIMITED [GB/GB]; 13 Station Road, Cambridge CB1 2JB (GB).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): SCHMIDT, Gunter [DE/GB]; Houghton Manor, Houghton, Cambs PE17 2BQ (GB). THOMPSON, Andrew, Hugin [GB/GB]; 25 Knoll Park, Alloway, Ayr KA7 4RH (GB).</p> <p>(74) Agents: DANIELS, Jeffrey, Nicholas et al.; Page White & Farrer, 54 Doughty Street, London WC1N 2LS (GB).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>

(54) Title: NUCLEIC ACID SEQUENCING

(57) Abstract

Provided is a method for sequencing DNA, which comprises: (a) obtaining a target DNA population comprising one or more single-stranded DNAs to be sequenced, each of which is present in a unique amount and bears a primer to provide a double-stranded portion of the DNA for ligation thereto; (b) contacting the DNA population with an array of hybridisation probes, each probe comprising a label cleavably attached to a known base sequence of predetermined length, the array containing all possible base sequences of that predetermined length; (c) removing all unligated probes; followed by the steps of: (d) cleaving the ligated probes to release each label; (e) recording the quantity of each label; and (f) activating the extended double-stranded portion to enable ligation thereto; wherein (g) steps (b) to (f) are repeated in a cycle for a sufficient number of times to determine the sequence of the or each single-stranded DNA by determining the sequence of release of each label.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakistan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

NUCLEIC ACID SEQUENCING

The present invention relates to a method for sequencing DNA and a kit for sequencing DNA.

Traditional methods for sequencing nucleic acid such as DNA frequently require biological sub-cloning hosts and vectors. Such traditional methods generally require gel chromatography to acquire sequence information. These traditional methods are therefore often complicated multi-stage processes which are both time-consuming and labour intensive.

PCT/US96/05245 discloses a method of nucleic acid sequencing based on an iterative process of duplex extension along a single-stranded template. Duplex extension is effected by ligating probes to a region of the template primed with an initialising oligonucleotide. The probes of the above method are labelled preferably with a fluorescent dye. The dye identifies a single base at the ligation site. The probes are prevented from uncontrolled extension by having removable blocking groups at one of their terminals.

PCT/GB95/00109 suggests a method of nucleic acid sequencing comprising sequentially extending a primer a pre-determined number of bases at a time, the added bases being complementary to the bases being sequenced. This is achieved by contacting the nucleic acid with a labelled adaptor, the label being specific to the base sequence of the adaptor. A population of adaptors is used having oligonucleotide sequences including all possible permutations for a pre-determined number of bases.

The present invention provides a method for sequencing DNA, which comprises:

(a) obtaining a target DNA population comprising one or more single-stranded DNAs to be sequenced, each of which is present in a unique amount and bears a primer to provide a double-stranded portion of the DNA for ligation thereto;

(2)

(b) contacting the DNA population with an array of hybridisation probes, each probe comprising a label cleavably attached to a known base sequence of predetermined length, the array containing all possible base sequences of that predetermined length and the base sequences being incapable of ligation to each other, wherein the contacting is carried out in the presence of ligase under conditions to ligate to the double-stranded portion of each DNA the probe bearing the base sequence complementary to the single-stranded DNA adjacent the double-stranded portion thereby to form an extended double-stranded portion which is incapable of ligation to further probes; and

(c) removing all unligated probes; followed by the steps of:

(d) cleaving the ligated probes to release each label;

(e) recording the quantity of each label; and

(f) activating the extended double-stranded portion to enable ligation thereto; wherein

(g) steps (b) to (f) are repeated in a cycle for a sufficient number of times to determine the sequence of the or each single-stranded DNA by determining the sequence of release of each label.

In one embodiment the array comprises a plurality of sub-arrays which together contain all the possible base sequences, and wherein each sub-array is contacted with the DNA population according to step (b), unligated probes are removed according to step (c), and these steps are repeated in a cycle before step (d) so that all of the sub-arrays contact the DNA population. In this way, the array of hybridisation probes is presented to the DNA population in stages. For example, where the predetermined length of base sequence is 4 and the total number of possible base sequences is 256 (4^4), cross-hybridisation between complementary 4-mer in the array can be avoided by contacting the DNA population with a first sub-array of 128 probes and, after removing all unligated probes, contacting with a second sub-array of 128 probes.

(3)

The target DNA population may be obtained by sorting an initial DNA sample into sub-populations and selecting one of the sub-populations as the target DNA population. Thus, if the initial DNA sample is large its size can be reduced by the sorting step. In a preferred arrangement, the initial DNA sample is cut into fragments, each having a sticky end of known length and unknown sequence, typically a length of from 2 to 6, preferably about 4 bases. The fragments may be sorted into sub-populations according to their sticky end sequence. It is thought that a population or sub-population of at least 60 fragments can be sequenced in parallel with an acceptable error rate using a probe with a base sequence of 4 bases.

Preferably, each single-stranded DNA is immobilised, usually at one end, for example on a solid support such as a bead. This has the advantage that removal of unwanted material can take place in solution and separation of the labels from the probes is facilitated. Preferably, the target DNA is immobilised prior to step (b) on the solid phase support. The solid phase support may conveniently be attached to the primer.

The label may be any suitable label such as a fluorescent label, a radio label or a mass label. The identity of the label must be assignable to the respective base sequence so that identification of the label identifies the base sequence. In a preferred arrangement, the label of each probe comprises a mass label. Each mass label is uniquely identifiable in relation to every other mass label using a mass spectrometer. Typically each mass label has a distinct mass from every other mass label and preferably a single ionization state at the pH of analysis in a mass spectrometer. Each mass label preferably does not fragment in the mass spectrometer. Preferred mass labels do not interfere with the action of the ligase in the sequencing method or with any other of the molecular biology steps used in the invention.

Where the label is a mass label, the quantity of each label corresponding to the ligated hybridisation probe is recorded in

(4)

step (e) after release of the label in step (d). Where the label is a fluorescent label, step (e) may precede step (d) and the quantity of fluorescent label present on the ligated probe is recorded before the label is released.

In any one cycle of the method according to the invention it is essential that the base sequence of only one probe ligates to the double-stranded portion of each DNA. The base sequences of the probes of the array are therefore incapable of ligation to each other so that the extended double-stranded portion which is formed after ligation is incapable of ligation to further probes. In subsequent step (f), the extended double-stranded portion is activated to enable ligation thereto of a further probe in the next cycle. The base sequences may be incapable of ligation to each other either by requiring activation or by being blocked to prevent ligation thereto.

In one embodiment of the invention the known base sequence is blocked at its 3'-OH. According to this embodiment, primer extension sequencing takes place in the 5' to 3' direction. In another embodiment of the invention, the base sequences are capable of ligating to each other only when activated by phosphorylation. According to this embodiment, the base sequence of each probe is unphosphorylated at both 3' and 5' ends and activation step (f) comprises phosphorylating the 5'-OH of the extended double-stranded portion to enable ligation thereto.

Advantageously, the step (d) of cleaving the ligated probes to release each label unblocks the 3'-OH of the extended double-stranded portion according to step (f). In other words, step (d) and step (f) are one and the same. Preferably, the label of each probe is cleavably attached to the 3'-OH of the base sequence. Thus, cleaving the label from the probe unblocks the 3'-OH so as to allow a new hybridisation probe to ligate thereto in the next sequencing cycle.

Theoretically the predetermined length of the base sequence is

(5)

limited only by considerations of ligase fidelity. The longer the base sequence, the stronger the hybridisation will be between probe base sequence and single-stranded DNA. Thus, a length of 10 or 11 is thought to be about the maximum before ligase fidelity becomes unacceptable. However, practically speaking, sequences of this length would require too many unique labels to be useful, whereas, shorter base sequences require fewer unique labels. Preferably, the predetermined length of the base sequence is from 2 to 6, more preferably 4.

The invention further provides a kit for sequencing DNA, which comprises an array of hybridisation probes, each probe comprising a label cleavably attached to a known base sequence of predetermined length, the array containing all possible base sequences of that predetermined length and the base sequences being incapable of ligation to each other. The array of hybridisation probes is preferably as defined above. The kit may further comprise instructions for use in a method of sequencing DNA. Use of the kit is therefore provided for a method of sequencing DNA, especially the method described above.

The invention will now be described in further detail by way of example only, with reference to the accompanying drawings, in which:-

FIGURES 1a and 1b show respectively first and second cycles of a preferred process according to the invention;

FIGURES 2a and 2b show respectively first and second cycles of an alternative process according to the invention;

FIGURE 3 shows typical adaptor molecules for use in the invention;

FIGURE 4 shows a preferred method of producing target DNA for sequencing in accordance with the invention;

FIGURE 5 shows a bar chart depicting the data for the first cycle of a 4-mer sequencing experiment, series 1 being without ligase and series 2 with ligase;

FIGURE 6 shows a bar chart depicting the data for the second

(6)

cycle of the 4-mer sequencing experiment, series 1 being without ligase and series 2 with ligase; and

FIGURE 7 shows a bar chart depicting the data for the third cycle of the 4-mer sequencing experiment, series 1 being without ligase and series 2 with ligase.

Parallel sequencing of sorted populations of nucleic acids by primer extension sequencing:

This invention is a process that allows a heterogenous population of nucleic acid fragments, generated by various means, to be sequenced simultaneously. The process provides a novel strategy for sequencing genomic DNA that potentially could avoid the need for biological subcloning hosts and vectors.

The sequencing process described here allows one to produce nucleic acid fragment populations in a reproducible manner that can then be sorted into subsets and finally sequenced by an iterative process of ligation of probes to an immobilised single-stranded DNA molecule.

Generation of a mixed nucleic acid population	→ Sort molecules into subsets	→ Sequence molecules within subsets simultaneously
---	----------------------------------	--

Outline of sequencing process.

The sequencing steps use short single stranded oligonucleotides of a predetermined length to probe the sequence of single-stranded immobilised template nucleic acid fragments. Single-stranded regions adjacent to a primed region are determined by ligating the probe oligonucleotides to the primer and determining their identity on the basis of a tag carried by the oligonucleotides. The label determines the sequence of the oligonucleotide probes. Nucleic acid fragments are probed as heterogenous sets and sequence information is determined by measuring the quantity of label of correctly hybridised and ligated probes.

Sequencing can be performed in either a 5' to 3' format or in a 3' to 5' format. Uncontrolled extension in the 5' to 3' format

(7)

is prevented by reversibly blocking the 3' -OH at the terminus of the probes prior to addition of the probes to the extending primer. After ligation of probe to primer any unligated probe is washed away. The quantity of ligated probes is determined and the 3' terminus is unblocked to allow the next cycle of probing to be performed on the extended primer. In the 3' to 5' format, uncontrolled extension of the primer is controlled by using a phosphorylation step to add a triphosphate entity onto the extending primer's 5' -OH group. Probes are synthesised without any phosphate groups at the 5' terminus, so after each addition of probes to the extending primer, the 5' -OH must be phosphorylated to permit further extension.

The sequence of individual fragments is determined by comparing quantities of label for each type of probe in each cycle of the sequencing process with quantities derived in previous and subsequent cycles. The invention provides a method for analysing heterogenous sub-populations of nucleic acids without spatially resolving them. This is achieved by a signal acquisition and signal processing procedure that allows sequences to be identified on the basis of their relative quantities.

This process does not require traditional gel methods to acquire sequence information. Since the entire process takes place in solution and is an iterative process, the steps involved could be performed by a liquid-handling robot.

Sequencing large nucleic acid molecules:

It is not necessary to sequence an entire molecule at once to determine its sequence, which is fortunate as it is a practical impossibility, at the moment, to sequence molecules as large as chromosomes. It is calculated that any given sequence 17 bp long should be unique within the human genome. Similar calculations can be performed for genomes that are of different sizes. This consideration means that large nucleic acids or entire genomes can be sequenced by degradation into short overlapping fragments, > 17 bp in length, which can then be sequenced and the total genome sequence can thence be reconstructed using software to determine contig overlaps.

Preparing a Nucleic Acid for Sequencing:

To sequence a complete nucleic acid of significant size is practically very difficult. This process requires fragmentation of the target nucleic acid and sorting into sub-populations that are small enough to allow simultaneous sequencing. Various embodiments of the sorting process have been described previously in the Gene Profiling patent application and the prior sequencing application. Only a minor variation in the use of adaptors to provide distinct termini in a population of generic nucleic acids is discussed here.

Immobilising a specific terminus in a population of nucleic acids:

An important factor is immobilisation of nucleic acids at one terminus. This requires that an arbitrarily generated fragment have directionality, i.e. it requires two distinguishable termini. This can be achieved using adaptors. Two types of adaptors are required to identify two distinct termini. Exemplary adaptors are shown in the attached figures. Adaptor 1 provides immobilisation and the recognition site for a type II restriction endonuclease that generates blunt-ended fragments, in this example the enzyme chosen is BsuRI which is methylation sensitive. DNA to be sequenced would be synthesised with 5-methyl cytosine while adaptors would be synthesised with unmethylated cytosine so that only adaptors would be sensitive to cleavage by BsuRI. Adaptor 2 provides a type II's restriction endonuclease recognition site or alternatively a restriction site for a second ordinary type II restriction endonuclease.

The adaptors need to be attached to the nucleic acid fragments. Effecting attachment depends on the means used to fragment the population, but assuming random fragmentation with some form of nuclease that generates known sticky-ends, ligation of forms of both adaptor types bearing complementary sequences will be effective or blunt-ended adaptors could be used as shown in Figure 3. This generates fragments of three types: fragments with both ends carrying adaptor 1, fragments with both ends carrying

adaptor 2 and thirdly fragments carrying adaptor 1 at one end and adaptor 2 at the other. Statistically the third type of fragment will be in the majority. If the immobilisation effector on adaptor 1 is biotin then the fragments carrying adaptor 1 can be immobilised on a solid phase matrix derivitised with avidin. The fragments carrying adaptor 2 at both ends can be washed away. Those fragments carrying two immobilisation adaptors might be immobilised at both termini depending on the fragment lengths. Cleavage with the type IIs restriction endonuclease whose binding site is carried by adaptor 2 will generate ambiguous sticky-ends at one terminus of the fragments bearing both types of adaptor. The fragments bearing two type 1 adaptors will be unchanged. The cleaved adaptor fragments can then be washed away with the type IIs restriction endonuclease. A second cleavage with the ordinary type II restriction endonuclease whose cleavage site is in adaptor 1 will release the remaining immobilised fragments that bore one copy of each adaptor at their termini. Those fragments should have an ambiguous sticky-end at the terminus that bore adaptor two and can thus be sorted as described below. Those fragments that carried two copies of adaptor 1 will have blunt-ended termini and will not bind the array and can thus be washed away. In this way a population of nucleic acid fragments can be specifically immobilised at one terminus with the other terminus prepared for sequencing. As long as multiple copies of each sequence is present then statistically the vast majority of sequences should be represented in the portion of the population carrying both adaptors and thus every sequence should be sequenced at least once. Any gaps should become apparent in the contig reconstruction process and can then be specifically searched for using primers targeted at sequences flanking the gaps.

Alternatively sorting can be left until a later step if adaptor 2 bore a cleavage site for an ordinary type II restriction endonuclease that generated a known sticky-end. Preferably a methylation sensitive restriction enzyme would be required to do

this. The resultant fragments can then be immobilised on beads for further processing such as further amplification or in order to render the fragments single-stranded. One skilled in the art could almost certainly think of other methods of achieving distinct termini. Furthermore, if a restriction map for the target DNA is known then designing adaptors or protocols to distinguish the termini of fragments is simpler.

Generating single-stranded DNA for primer extension sequencing:

This sequencing system requires single-stranded DNA fragments to operate on. This is relatively trivial to generate. One need only use beads derivitised with a double-stranded oligonucleotide that has no terminal phosphate groups on its exposed 5' strand. Cleavage of the DNA fragments to be sequenced with an enzyme that leaves 5' phosphates or use of a kinase to generate 5' phosphate groups on these fragments is required so that ligation of these fragments to the beads can take place, see Figure 4. The ligation will leave the strand linked to the 5' terminus of the immobilised oligonucleotide with a nick. Raising the temperature or otherwise producing denaturing conditions will remove the nicked strand, leaving an immobilised single stranded DNA.

DNA from phage M13 is single-stranded and this is often used as a sequencing vector to generate single-stranded templates for Sanger sequencing.

Sorting molecules into subsets:

Once a fragment population has been amplified and distinct termini established for each fragment, as described above the fragments with ambiguous sticky-ends can be sorted. Sorting can be effected in the same way as described in the Gene Profiling application GB 9618544.2 using beads derivitised with oligonucleotides complementary to the possible sticky-ends that might be generated. The sorting process can be repeated with the first sorted populations using adaptors to provide another

terminal type IIs restriction endonuclease site. This will allow another set of ambiguous sticky-ends to be generated allowing further sub-sorting until the nucleic acid fragment population is of the correct size for unambiguous sequence determination.

One can effect also sorting with oligonucleotides chips, allowing simultaneous analysis of fragments. This is particularly desirable as the quantities of reagents required would be much smaller than for a series of wells. This sorting method is compatible with fluorescence as a means of detection. A population of DNA fragments with an ambiguous sticky-end at one terminus can be sorted on an oligonucleotide chip by ligation of the exposed sticky-end to its complement. Thus for a 4 bp sticky-end, a chip with the 256 possible 4-mers present at discrete locations on its surface would be required.

This sorting process above generates, for a 4 bp ambiguous sticky-end, 256 sub-populations. This may generate nucleic acid populations small enough to begin sequencing or further sub-sorting may be necessary.

Primer Extension and Parallel Sequencing of Heterogenous Populations of Nucleic Acid Fragments:

Sequencing a single molecule by ligation of single stranded oligonucleotides to a primer:

This process can be understood first by explaining it for the case of a single nucleic acid. Consider a single nucleic acid, immobilised at one terminus to a fixed insoluble matrix. This molecule is rendered single stranded, except for a short stretch of double-stranded DNA at the immobilised terminus of the molecule. This primer sequence could be provided by the adaptor used to immobilise the terminus.

To determine the sequence of this single-stranded molecule one can probe the immobilised nucleic acid with every one of the

(12)

possible 256 single-stranded 4 base oligonucleotides. Each of these would carry a unique identifying label corresponding to its known, sequence of 4 bp. In the 5' to 3' format (see Figures 2a and b), the label could be attached to the 3' -OH effectively blocking them from further extension, or a separate blocking group can be used and the label can be attached elsewhere in the molecule. In the 3' to 5' format (see Figures 1a and b) there is no particular advantage in attaching the mass label to any particular part of the probe, except that it is less likely to interfere with the ligase if it is added to the terminus of the probe.

If the oligonucleotides are added in the presence of a ligase, the oligonucleotide complementary to the 4 bases of sequence adjacent to the primed double-stranded region, will be ligated to the primer. The immobilised matrix can then be washed to remove any unbound oligonucleotides. To determine the sequence of the 4 base oligonucleotide that ligated to the primer, one need only analyse the label attached to the 3' end of the oligonucleotide. The labelling system for use with this invention is described in a PCT patent application filed concurrently with the present application (Page White & Farrer Ref: 86359). This describes 'mass labelling' in which the mass of the label identifies its carrier. Such labels can be made photolabile or cleavable by a specific agent. Cleavage of the label will release it into solution in which it can be injected into an electrospray mass spectrometer for analysis, which will determine the sequence of the oligonucleotide and furthermore, its quantity.

In the preferred embodiment, a photolysable linker would connect the mass label to the 3'-OH which when cleaved would regenerate the 3'-OH with as high an efficiency as possible. The primer has then been extended by 4 known bases and the cycle can be repeated to determine the next 4 bp of sequence. This process can be repeated iteratively until the entire molecule has been

sequenced.

An alternative implementation to using photolysable mass labels at the 3'-OH of each 4-mer oligonucleotide would be to cap the 3'-OH with a phosphate group. The mass-label could be attached to another part of the molecule from which it can be released independently of the uncapping reaction of the 3' terminus. Uncapping of the 3' terminus can be effected by washing the immobilised DNA with alkaline phosphatase which will readily remove the capping phosphate from the 3'-OH leaving it available for the next cycle of the sequencing process.

Conceivably this system could be implemented with other labelling schemes, but most other labelling schemes do not generate sufficient, unique labels to be practical. Using fluorescence the same system could be implemented, but since only 4 good dyes are commercially available, the 4 bp oligonucleotides would have to be tested in 64 groups of 4, rather than all at once. Similar considerations apply to use of radiolabels, but here, each oligo would be added one at a time. Other labels include carbohydrates, biotin amongst others.

Actually mass-labelled oligonucleotides would probably be added in two sets of 128 such that each member in the first set would have its complement in the other set. This overcomes the problem of cross-hybridisation between complementary 4-mers.

Sequencing a Population of Nucleic Acid Fragments:

The same process can be applied to a heterogeneous population of immobilised nucleic acids allowing them to be analysed in parallel. To be successful when applied to a population of nucleic acids, this method relies on the assumption that statistically 1 out of 256 molecules within the total population will carry each of the possible 4 bp sequences adjacent to the double stranded primer region. If one sub-sorts one's nucleic acid population into manageable subsets of less than 256

(14)

fragments, one would expect that almost all will have different ambiguous sticky-ends (there is about a 1 in 1000 chance of there being 2 distinct DNAs having the same 4 bp sequence at any given point if 100 distinct sequences are analysed simultaneously) so for most purposes one can assume that a hybridisation signal corresponds to a single DNA type. This all assumes that DNA sequences are random sequences of bases which is not strictly true but is a sufficient assumption for the purposes of this invention. Obviously 1 in a 1000 is not a small probability and sequences will often have the same 4-mer in a sequencing cycle. However this invention includes an algorithm that can resolve to a great extent any possible ambiguities caused by this occurrence.

Reconstructing Sequences of Target Nucleic Acids:

Repetitions of the primer extension cycle will generate a matrix of quantities of label corresponding to each possible probe. Shown below is a possible matrix for all probes of 4 base pairs in length:

Sequence to which label corresponds	Cycle 1	Cycle 2	Cycle 3	Cycle 4
AAAA	5	24	13	7
AAAC	10	5	9	13
AAAG	13	9	15	17
.....
TTTG	7	13	17	10
TTTT	17	10	7	14

To reconstruct the sequences to which these quantities of label correspond, this invention may incorporate an algorithm for analysing such a data matrix. Such an algorithm and a computer program for employing the algorithm are described in detail in PCT/GB97/02734. The algorithm attempts to identify a sequence

(15)

on the basis of its frequency, i.e. a sequence present at a given frequency will have every subsequence present at the same frequency. The algorithm searches through each column of the matrix and attempts to resolve label quantities, that may be sums of sequence frequencies into atomic quantities such that the same set of atomic quantities appear in all columns. The algorithm achieves this by comparing label quantities in a given column with those in the previous and the subsequent columns, except in the case of the first and last columns which can only be compared with the following and previous columns respectively. A given atomic quantity that appears in all columns is then assumed to correspond to a unique sequence.

If two sequences have the same n-mer at a particular point in the sequence, these can be resolved by the quantitative nature of this system in that the quantity of a particular n-mer in a particular ligation will be the sum of the quantities of the two sequences that share the n-mer at the same point. These can be largely resolved by comparison of one cycle with previous and subsequent ligation cycles to identify such sums. This is made particularly simple if the sequences that are being analysed have been amplified by PCR such that the sequence in the lowest quantity is present at not less than half the quantity of the sequence with the greatest frequency, that is to say if the frequency range of sequences lies between some quantity N and $2N$. This means that any sum of frequencies will be greater than $2N$ and hence readily detectable.

There may be occasional ambiguities that only give partial resolution of the sequences. Further resolution can be obtained by performing the same sequencing process for each sample twice. In each case the length of the probe is different, so for the first sequencing attempt, probes of 4 base pairs would be used and for the second, probes of 5 base pairs would be used. Comparison of the two matrices will allow the sequences to be resolved with far fewer ambiguities.

(16)

Implementation of the invention:

Practical details of implementing the process are described below.

Adaptors, PCR Primers and Oligonucleotides:Construction of Oligonucleotides, Adaptors, Primers, etc:

Details and reviews on the construction of oligonucleotides are available in numerous up to date texts, which should allow one skilled in the art to construct primers, adaptors and any other oligonucleotides required by the invention:

- Gait, M.J. editor, 'Oligonucleotide Synthesis: A Practical Approach', IRL Press, Oxford, 1990
- Eckstein, editor, 'Oligonucleotides and Analogues: A Practical Approach', IRL Press, Oxford, 1991
- Kricka, editor, 'Nonisotropic DNA Probe Techniques', Academic Press, San Diego, 1992
- Haugland, 'Handbook of Fluorescent Probes and Research Chemicals', Molecular Probes, Inc., Eugene, 1992
- Keller and Manack, 'DNA Probes, 2nd Edition', Stockton Press, New York, 1993
- Kessler, editor, 'Nonradioactive Labeling and Detection of Biomolecules', Springer-Verlag, Berlin, 1992.

Of particular importance is the chemistry used to cap the 3'-OH of the probe oligonucleotides. Acid labile and base labile groups are well known and discussed in the texts above. Capping with a phosphate group is also possible using the above texts, such a group can then be controllably removed using a phosphatase such as alkaline phosphatase which is readily available.

Conditions for Using Oligonucleotide Constructs:

Details on effects of hybridisation conditions for nucleic acid

(17)

probes can be found in be found in references below:

- Wetmur, Critical Reviews in Biochemistry and Molecular Biology, 26, 227-259, 1991
- Sambrook et al, 'Molecular Cloning: A Laboratory Manual, 2nd Edition', Cold Spring Harbour Laboratory, New York, 1989
- Hames, B.D., Higgins, S.J., 'Nucleic Acid Hybridisation: A Practical Approach', IRL Press, Oxford, 1988

Ligation:

Ligation of oligonucleotides is a critical aspect of the invention that must be considered. Chemical methods of ligation are known:

- Ferris et al, Nucleosides and Nucleotides_8, 407 - 414, 1989
- Shabarova et al, Nucleic Acids Research 19, 4247 - 4251, 1991

Preferably enzymatic ligation would be used as this has much higher fidelity. Preferred ligases would be T4 DNA ligase, T7 DNA ligase, E. coli DNA ligase, Taq ligase, Pfu ligase and Tth ligase. References to the literature are given below:

- Lehman, Science 186, 790 - 797, 1974
- Engler et al, 'DNA Ligases', pg 3 - 30 in Boyer, editor, 'The Enzymes, Vol 15B', Academic Press, New York, 1982

Protocols for use of ligases can be found in:

- Sambrook et al, cited above
- Barany, PCR Methods and Applications, 1: 5 - 16, 1991
- Marsh et al, Strategies 5, 73 - 76, 1992

Phosphorylation of Nucleic Acids:

When ligases and restriction endonucleases are used, there are changes made to the 5' phosphates of nucleic acid backbone sugar molecules. It is critical to this invention that extension of primers by ligated oligonucleotides be tightly controlled such that only one oligonucleotide is ligated to each extending primer in each cycle of the sequencing process. It is also possible to alter the phosphorylation state of oligonucleotides, adaptors or target nucleic acids during their synthesis or later, in versions of the process. Included are references to literature regarding use of phosphatases, kinases and chemical methods:

- Horn and Urdea, Tetrahedron Lett. 27, 4705, 1986
- Sambrook et al, cited above

The 5'-hydroxyl gp of the oligonucleotides can be chemically phosd. by means of phosphoryl chloride (POCl_3).

Restriction Endonucleases:

Numerous type II and IIs restriction endonucleases exist and could be used with this invention. Table 1 below gives a list of examples but is by no means comprehensive. A literary review of restriction endonucleases can be found in Roberts, R., J. Nucl. Acids Res. 18, 2351 - 2365, 1988. New enzymes are discovered at an increasing rate and more up to date listings are recorded in specialist databases such as REBase which is readily accessible on the internet using software packages such as Netscape or Mosaic and is found at the World Wide Web address: <http://www.neb.com/rebase/>. REBase lists all restriction enzymes as they are discovered and is updated regularly, moreover it lists recognition sequences, isoschizomers of each enzyme, manufacturers and suppliers and references to them in scientific literature. The protocol would be much the same irrespective of the type IIs restriction endonuclease used but the spacing of recognition sites for a given enzyme within an adaptor would be tailored according to requirements and the enzymes cutting behaviour. (see figure n above)

Enzyme Name	Recognition sequence	Cutting site
FokI	GGATG	9/13
BstFsl	GGATG	2/0
SfaNI	GCATC	5/9
HgaI	GACGC	5/10
BbvI	GCAGC	8/12

Table 1: A sample of type IIs restriction endonucleases

The requirement of the process is the generation of ambiguous sticky-ends at the termini of the nucleic acids being analysed. This could also be achieved by controlled use of 5' to 3' exonucleases. Clearly any method that achieves the creation of such sticky-ends will suffice for the process.

Similarly ordinary type II restriction endonucleases required by this invention can be found in the reference sources listed above. Details on methylation sensitivity and other means of controlling enzyme action can be found in the references given in REBase or can be acquired from the manufacturers.

Solid Phase Supports:

A full discussion of solid phase supports can be found in Brenner PCT/US95/12678 pg 12 - 14. This is an important issue in the use of fluorimetry to determine sequence abundance in that the design of supports will affect the acquisition of fluorescent signals which must be maximised for this process to be effective.

Mass Spectrometry of labels on oligonucleotides:

Electrospray mass spectrometry is the preferred technique for identification of labels attached to oligonucleotides since it is a very soft technique and can be directly coupled to the

liquid phase molecular biology used in this invention. For a full discussion of mass spectrometry techniques see:

- R.A.W. Johnstone and M.E. Rose, "Mass Spectrometry for chemists and biochemists" 2nd edition, Cambridge University Press, 1996.

Mass labels:

For any practically or commercially useful system it is important that construction of labels be as simple as possible using as few reagents and processing steps as possible. A combinatorial approach in which a series of monomeric molecular units are available to be used in multiple combinations with each other

Amino acids:

With a small number of amino acids such as glycine, alanine and leucine, a large number of small peptides with different masses can be generated using standard peptide synthesis techniques well known in the art. With more amino acids many more labels can be synthesised.

- E. Atherton and R.C. Sheppard, editors, 'Solid Phase Peptide Synthesis: A Practical Approach', IRL Press, Oxford.

Carbohydrates:

Similarly carbohydrate molecules are useful monomeric units that can be synthesised into heteropolymers of differing masses but these are not especially amenable to ESMS.

- Gait, M.J. editor, 'Oligonucleotide Synthesis: A Practical Approach', IRL Press, Oxford, 1990

- Eckstein, editor, 'Oligonucleotides and Analogues: A Practical Approach', IRL Press, Oxford, 1991

Other labelling chemistries:

Clearly almost any molecule can be tacked onto another as a label. Obviously the properties of such labels in the mass-spectrometer will vary. In terms of analysing biomolecules it will be important that the labels be inert, etc, as discussed previously. Cholesterol groups and glyceryl groups are possibilities that could be used but these are intrinsically relatively large molecules and the scope.

Designing molecules with favorable mass-spectrometry purposes:

One can synthesis labels using standard organic chemistry techniques. Such labels ought to carry amine derivatives, quaternary ammonium ions or positive sulphur centres if positive ions are sought. These have extremely good detection properties that generate clean sharp signals. Similarly, negatively charged ions can be used, so molecules with carboxylate moieties can be used. Labels for MALDI mass spectrometry can be generated by derivitising known molecules that are excitable by UV laser light, such as sinapinnic acid or cinnamic acid, of which a number of derivatives are already commercially available. For a text on organic chemistry see:

- Vogel's "Textbook of Organic Chemistry" 4th Edition, Revised by B.S. Furniss, A.J. Hannaford, V. Rogers, P.W.G. Smith & A.R. Tatchell, Longman, 1978.

Linkers:

An important feature of this invention is attachment of labels to their relevant biomolecules and in the 5' to 3' sequencing embodiment, the need for removable blocking groups is also critical. For details on these issues see:

- Theodora W. Greene, "Protective Groups in Organic Synthesis", 1981, Wiley-Interscience

Fluorimetry:

Certain embodiments of the process could use oligonucleotides

(22)

bearing fluorescent labels. Detection of fluorescent signals can be performed using optical equipment that is readily available. Fluorescent labels usually have optimum frequencies for excitation and then fluoresce at specific wavelengths in returning from an excited state to a ground state. Excitation can be performed with lasers at specific frequencies and fluorescence detected using collections lenses, beam splitters and signal distribution optics. These direct fluorescent signals to photomultiplier systems which convert optical signals to electronic signals which can be interpreted using appropriate electronics systems.

Brenner PCT/US95/12678 pg 26 - 28 gives a full discussion.

Liquid Handling Robotics:

For this process to be practically useful, automation is essential and liquid handling robots can be acquired from various sources such as Applied Biosystems.

Example-Sequencing by the ligation of 4-mers

An experiment was carried out involving the extension of a sequencing primer, hybridised to a single stranded DNA template, by the stepwise ligation of 4mers. In general the 4mers will contain labels with which the sequence of the 4mer and hence the template can be derived. 256 4mers are required to cover all possible variations. Each 4mer must contain a blocking group, preferably the identifying label, at the 3'hydroxyl to ensure that only one 4mer is ligated to the sequencing primer with each cycle. After successful ligation the blocking group (and the label if different) is removed by chemical or other means to expose the 3'hydroxyl of the 4mer. The label, and hence the sequence, is then identified. The 4mer is then available for the ligation of the next 4mer in the second cycle.

In order to demonstrate the effectiveness of removing of the 3'blocking group of the ligated 4mer a non-blocked 4mer was

(23)

ligated to the sequencing primer in a separate reaction and this was then used as a template for the next cycle. The Experiment is depicted in schematic form below:

Sequencing template - captured to streptavidin coated plate via a biotin molecule (B):

5' CTGGTACGTACATACGACTA' 3OH

3' GACCATGCATGTATGCTGATACAGATGAATGTATTTGATAGTCCTAGCTAAAG5' B

Cycle 1

5' CTGGTACGTACATACGACTA' 3OH

3' GACCATGCATGTATGCTGATACAGATGAATGTATTTGATAGTCCTAGCTAAAG5' B

+

5' PO4-TGTC-3' FAM, 5' PO4-TACT-3' FAM, 5' PO4-TAAA-3' FAM

=

5' CTGGTACGTACATACGACTA-TGTC-FAM

3' GACCATGCATGTATGCTGAT-ACAGATGAATGTATTTGATAGTCCTAGCTAAAG5' B

Only 5' PO4-TGTC-3' FAM ligates to give a signal which identifies the first 4 bases ('3ACAG'5) of the template.

To simulate the deprotection of the above species the following reaction was carried out:

5' CTGGTACGTACATACGACTA' 3OH

3' GACCATGCATGTATGCTGATACAGATGAATGTATTTGAT (N) 14-5' B

+

5' PO4-TGTC-3' OH

=

5' CTGGTACGTACATACGACTA-TGTC-3' OH

(24)

3' GACCATGCATGTATGCTGAT-ACAGATGAATGTATTTGAT (N) 14-5' B

The above species was then used as a template for Cycle 2.

Cycle 2

5' CTGGTACGTACATACGACTA-TGTC-3' OH

3' GACCATGCATGTATGCTGAT-ACAGATGAATGTATTTGAT (N) 14-5' B

+

5' PO4-TGTC-3' FAM, 5' PO4-TACT-3' FAM, 5' PO4-TAAA-3' FAM

=

5' CTGGTACGTACATACGACTA-TGTC-TACT-FAM

3' GACCATGCATGTATGCTGAT-ACAG-ATGAATGTATTTGAT (N) 14-5' B

Only 5' PO4-TACT-3' FAM ligates to give a signal which identifies the next 4 bases (3ATGA'5) of the template.

Also to simulate the deprotection of the above species the following reaction was carried out:

5' CTGGTACGTACATACGACTA-TGTC-3' OH

3' GACCATGCATGTATGCTGAT-ACAGATGAATGTATTTGAT (N) 14-5' B

+

5' PO4-TACT-3' OH,

=

5' CTGGTACGTACATACGACTA-TGTC-TACT-OH

3' GACCATGCATGTATGCTGAT-ACAG-ATGAATGTATTTGAT (N) 14-5' B

The above species was then used as a template for Cycle 3.

(25)

Cycle 3

5' CTGGTACGTACATACGACTA-TGTC-TACT-OH

3' GACCATGCATGTATGCTGAT-ACAG-ATGAATGTATTTGAT (N) 14-5' B

+

5' PO4-TGTC-3' FAM, 5' PO4-TACA-3' FAM, 5' PO4-TAAA-3' FAM

=

5' CTGGTACGTACATACGACTA-TGTC-TACT-TACA-FAM

3' GACCATGCATGTATGCTGAT-ACAG-ATGA-ATGTATTTGAT (N) 14-5' B

Only 5' PO4-TACA-3' FAM ligates to give a signal which identifies the next 4 bases (3ATGT'5) of the template.

Therefore, through 3 cycles of ligation of 4mers the sequence ACAGATGAATGT of the template was deduced.

Materials:

Oligonucleotides:

sequencing primer

5' CTGGTACGTACATACGACTA' 3OH

sequencing template (contains a 5' biotin molecule)

3' GACCATGCATGTATGCTGATACAGATGAATGTATTTGATAGTCCTAGCTAAAG5' B

4mers used

(26)

5' PO4-TGTC-3' FAM, 5' PO4-TACT-3' FAM, 5' PO4-TAGA-FAM,
5' PO4-TACA-FAM, 5' PO4-TGTC-3' OH, 5' PO4-TACT-3' OH

All oligos were synthesised by Oswel DNA (UK).

Solutions:

wash solution 50mM Tris-HCl pH7.6
 10mM MgCl₂

binding solution 50mM Tris-HCl pH7.6
 10mM MgCl₂
 1M NaCl

ligase buffer 50mM Tris-HCl pH7.6
 10mM MgCl₂
 10mM DTT
 1mM ATP
 50ug/ml BSA

Methods:**Hybridisation of the sequencing primer to the template**

Aliquots with 500ul of 0.5 times binding solution containing 5pmol/ul of each of the sequencing primer and template were heated at 95oC for 5 mins and then allowed to cool to room temperature over 2 hours. They were then incubated at 4oC for 1 hour and frozen at -20oC until used.

This will now be referred to as 'the sequencing template'.

(27)

Capture of the Sequencing Template

20pmol (4ul) + 21ul of binding solution was added to each well of a black streptavidin coated 96 well microtitre plate (Boehringer Mannheim) and incubated at room temperature for 1 hour. The wells were then washed twice with 200ul of wash solution and once with 50ul of ligase buffer. The plates were then stored at 4oC until used.

Cycle 1

Three groups of reactions, one group with a specific 4mer (TGTC) and two with non-specific 4mers (TACT and TAAA) were set up as follows.

Four reactions were set up containing 5% PEG, 400 units of ligase (New England Biolabs) and 100 pmol of 4mer in 25 ul of ligase buffer for the following 4mers: 5'PO4-TGTC3'-FAM, 5'PO4-TACT3'-FAM and 5'PO4-TAAA3'-FAM. Also four reactions for the same 4mers were set up in the same way, but without the inclusion of the ligase to control for non-specific binding of the 4mers.

To simulate a deprotected, successfully ligated 4mer to the sequencing template 48 reactions containing 5% PEG, 400 units of ligase (New England Biolabs) and 100 pmol of 5'PO4-TGTC3'OH in 25 ul of ligase buffer were set up.

The above reactions were then added to wells of the microtitre plate containing the sequencing template and incubated at 4oC for 30 minutes followed by 16oC for 1 hour. The wells were then washed 3 times with 100ul of wash solution. 100ul of wash solution was added to each well. The amount of 4mer ligated to the sequencing template was assessed by measuring the Florescence of any FAM molecule present using a Biolumin 960 fluorescent

(28)

microtitre plate reader (Molecular Dynamics) using the Xperiment 1.1.0 software (Molecular Dynamics).

Data for Cycle 1

The following data for Cycle 1 are expressed as relative fluorescent units (RFUs) obtained from the reactions which contained ligase:

	TAAA-FAM	TACT-FAM	TGTC-FAM
	10764	10878	120119
	9815	9994	97638
	11635	12543	98891
	12031	11188	95931
mean	11069	11151	103145

The following data from Cycle 1 are expressed as relative fluorescent units (RFUs) obtained from the reactions which did not contain ligase:

	TAAA-FAM	TACT-FAM	TGTC-FAM
	14605	13987	15134
	13638	13692	15370
	13938	14823	16019
	13826	13117	17849
mean	14002	13905	16093

These data clearly show that TGTC-FAM has been specifically ligated to the sequencing template. The other 4mers, in the

(29)

presence of ligase, gave signals similar to those obtained from non-specific hybridisation control reactions.

Therefore, this specific signal provides the first 4 bases (3'ACAG5') of the sequencing template.

Cycle 2

The following reactions were applied to the sequencing template to which the specific 5'PO4-TGTC-3'OH 4mer had been ligated (as described in Cycle 1) to mimic a 4mer which had been deprotected/identified.

Three groups of reactions, one group with a specific 4mer (TACT) and two with non-specific 4mers (TGTC and TAAA) were set up as follows.

Four reactions were set up containing 5% PEG, 400 units of ligase (New England Biolabs) and 100 pmol of 4mer in 25 ul of ligase buffer for the following 4mers: 5'PO4-TGTC3'-FAM, 5'PO4-TACT3'-FAM and 5'PO4-TAAA3'-FAM. Also four reactions for the same 4mers were set up in the same way but without the inclusion of the ligase to control for non-specific binding of the 4mers.

To simulate a deprotected, successfully ligated 4mer to the sequencing template 24 reactions containing 5% PEG, 400 units of ligase (New England Biolabs) and 100 pmol of 5'PO4-TACT3'OH in 25 ul of ligase buffer were set up.

The above reactions were then added to wells of the microtitre plate containing the sequencing template, with 5'PO4-TGTC-3'OH

(30)

ligated to it as described in cycle 1, and incubated at 40C for 30 minutes followed by 160C for 1 hour. The wells were then washed 3 times with 100ul of wash solution. 100ul of wash solution was added to each well the amount of 4mer ligated to the sequencing template was assessed by measuring the Florescence of any FAM molecule present using a Biolumin 960 fluorescent microtitre plate reader (Molecular Dynamics) using the Xperiment 1.1.0 software (Molecular Dynamics).

Data for Cycle 2

The following data for Cycle 2 are expressed as relative fluorescent units (RFUs) obtained from the reactions which contained ligase:

	TAAA-FAM	TACT-FAM	TGTC-FAM
	9238	24071	9693
	8207	24455	9415
	10312	23194	11071
	9153	21641	10815
mean	9227	23340	10248

The following data from Cycle 2 are expressed as relative fluorescent units (RFUs) obtained from the reactions which did not contain ligase:

TAAA-FAM	TACT-FAM	TGTC-FAM
12532	16025	13917
11947	15651	13573
12040	17587	13049

(31)

	11908	16464	12998
mean	12107	16432	13384

As with Cycle 1, Cycle 2 produces a clear signal from the specific 4mer ligation as compared to the non-specific 4mer ligations and the non-specific hybridisation control reactions which lacked ligase.

Therefore cycle 2 has produced the next 4 bases (3'ATGA5') of the sequencing template.

Cycle 3

The following reactions were applied the sequencing template to which the specific 5'PO₄-TACT-3'OH 4mer had been ligated (as described in Cycle 2) to mimic a 4mer which had been deprotected/identified.

Three groups of reactions, one group with a specific 4mer (TACA) and two with non-specific 4mers (TGTC and TAAA) were set up as follows.

Four reactions were set up containing 5% PEG, 400 units of ligase (New England Biolabs) and 100 pmol of 4mer in 25 ul of ligase buffer for the following 4mers: 5'PO₄-TGTC3'-FAM, 5'PO₄-TACT3'-FAM and 5'PO₄-TAAA3'-FAM. Also four reactions for the same 4mers were set up in the same way, but without the inclusion of the ligase to control for non-specific binding of the 4mers.

The above reactions were then added to wells of the microtitre plate containing the sequencing template, with 5'PO₄-TACT-3'OH

(32)

ligated to it as described in cycle 2, and incubated at 40C for 30 minutes followed by 160C for 1 hour. The wells were then washed 3 times with 100ul of wash solution. 100ul of wash solution was added to each well the amount of 4mer ligated to the sequencing template was assessed by measuring the Florescence of any FAM molecule present using a Biolumin 960 fluorescent microtitre plate reader (Molecular Dynamics) using the Xperiment 1.1.0 software (Molecular Dynamics).

Data for Cycle 3

The following data for Cycle 3 are expressed as relative fluorescent units (RFUs) obtained from the reactions which contained ligase:

	TAAA-FAM	TACA-FAM	TGTC-FAM
	8294	61002	10307
	8136	52253	9659
	10323	53848	11894
	9424	51570	12443
mean	9044	54668	11076

The following data from Cycle 2 are expressed as relative fluorescent units (RFUs) obtained from the reactions which did not contain ligase:

TAAA-FAM	TACA-FAM	TGTC-FAM
11605	16641	14000
11417	15414	14704
11995	17719	14443

(33)

	11959	16021	14381
mean	11744	16449	14382

As with Cycles 1 and 2, Cycle 3 produces a clear signal from the specific 4mer ligation as compared to the non-specific 4mer ligations and the non-specific hybridisation control reactions which lacked ligase.

Therefore cycle 3 produced the next 4 bases (3'ATGT5') of the sequencing template.

A total of 12 bases (3'ACAGATGAATGT5') were successfully sequenced by three rounds of ligations using a fluorescent system which does not require the use of gel electrophoresis.

The specific 4mers (e.g. TACA in Cycle 3) generally give a slightly higher reading in the non-specific hybridisation reactions, without ligase, compared to the non-specific 4mers. This is due to the fact that they are hybridising to their specific target on the sequencing template and are not being fully removed in the washing steps. These slightly higher signals could be reduced to the levels of the non-specific 4mers by increasing the stringency of the washing steps by lowering the ionic strength or increasing the temperature of the wash solution.

The signals obtained for the reactions with ligase of the mis-matched 4mers are lower than those obtained from the non-specific hybridisation control reactions. This is probably due to the presence of a substance in the ligase solution, which is not being removed by the washing steps, quenching some of the fluorescence. This difference could be removed by improving the

(34)

washing steps or by including inactivated ligase solution into these reactions thereby insuring the same amount of quenching in all reactions.

To ensure that the maximum possible number of cycles may be carried out using this method, it is important to ensure that the ligation efficiency is very high for each step, so that sufficient template is produced for the next cycle.

CLAIMS:

1. A method for sequencing DNA, which comprises:

(a) obtaining a target DNA population comprising one or more single-stranded DNAs to be sequenced, each of which is present in a unique amount and bears a primer to provide a double-stranded portion of the DNA for ligation thereto;

(b) contacting the DNA population with an array of hybridisation probes, each probe comprising a label cleavably attached to a known base sequence of predetermined length, the array containing all possible base sequences of that predetermined length and the base sequences being incapable of ligation to each other, wherein the contacting is carried out in the presence of ligase under conditions to ligate to the double-stranded portion of each DNA the probe bearing the base sequence complementary to the single-stranded DNA adjacent the double-stranded portion thereby to form an extended double-stranded portion which is incapable of ligation to further probes; and

(c) removing all unligated probes; followed by the steps of:

(d) cleaving the ligated probes to release each label;

(e) recording the quantity of each label; and

(f) activating the extended double-stranded portion to enable ligation thereto; wherein

(g) steps (b) to (f) are repeated in a cycle for a sufficient number of times to determine the sequence of the or each single-stranded DNA by determining the sequence of release of each label.

2. A method according to claim 1, wherein the array comprises a plurality of sub-arrays which together contain all the possible

base sequences, and wherein each sub-array is contacted with the DNA population according to step (b), unligated probes are removed according to step (c), and these steps are repeated in a cycle before step (d) so that all of the sub-arrays contact the DNA population.

3. A method according to claim 1 or claim 2, wherein the target DNA population is obtained by sorting an initial DNA sample into sub-populations and selecting one of the sub-populations as the target DNA population.

4. A method according to claim 3, wherein the initial DNA sample is cut into fragments, each having a sticky end of known length and unknown sequence, which fragments are sorted into sub-populations according to their sticky end sequence.

5. A method according to any one of the preceding claims, wherein each single-stranded DNA is immobilised at one end.

6. A method according to any one of the preceding claims, wherein the label of each probe comprises a mass label, and the quantity of each label is recorded according to step (e) using mass spectrometry after release of the label in step (d).

7. A method according to any one of the preceding claims, wherein the known base sequence is blocked at its 3'OH.

8. A method according to claim 7, wherein the step (d) of cleaving the ligated probes to release each label unblocks the 3'-OH of the extended double-stranded portion according to step (f).

(37)

9. A method according to claim 8, wherein the label of each probe is cleavably attached to the 3'-OH of the base sequence.

10. A method according to any one of claims 1 to 6, wherein the base sequence of each probe is unphosphorylated at both 3' and 5' ends and step (f) comprises phosphorylating the 5'-OH of the extended double-stranded portion.

11. A method according to any one of the preceding claims, wherein the predetermined length of the base sequence is from 2 to 6.

12. A method according to claim 11, wherein the predetermined length of the base sequence is 4.

13. A kit for sequencing DNA, which comprises an array of hybridisation probes, each probe comprising a label cleavably attached to a known base sequence of predetermined length, the array containing all possible base sequences of that predetermined length and the base sequences being incapable of ligating to each other.

14. A kit according to claim 13, wherein the known base sequence is blocked at its 3'-OH.

15. A kit according to claim 14, wherein the label of each probe is cleavably attached to the 3'-OH of the base sequence to prevent ligation thereto.

16. A kit according to any one of claims 13 to 15, wherein the base sequence of each probe is unphosphorylated at both 3' and

5' ends.

17. A kit according to any one of claims 13 to 16, wherein the label of each probe comprises a mass label.

18. A kit according to any one of claims 13 to 17, wherein the predetermined length of the base sequence is from 2 to 6.

19. A kit according to claim 18, wherein the predetermined length of the base sequence is 4.

20. Use of a kit according to any one of claims 13 to 19 for a method of sequencing DNA.






FIG. 1A








FIG. 2B

BIOTIN — NNNGGCC
 NNNCCGG
ADAPTOR 1

BspMI RECOGNITION
SEQUENCE
 ↓
 NNNGCAGGTNNNN
 NNNCGTCCANNNN
ADAPTOR 2


THIS ADAPTOR WOULD ALLOW
FRAGMENTS TO BE SORTED AFTER A
DETERMINING A TERMINUS.

BsaI RECOGNITION
SEQUENCE
 ↓
 NNNGGTCTCNNNN
 NNNCCAGAGNNNN
ALTERNATIVE
ADAPTOR 2

THIS ADAPTOR WOULD ALLOW
FRAGMENTS TO BE REIMMOBILISED
ON BEADS USING THE KNOWN BsaI
STICKY-END. THIS WOULD ALLOW
FURTHER PROCESSING BEFORE
BEGINNING TO SEQUENCE.

FIG. 3

ADAPTORS TO GENERATE DISTINCT
TERMINI IN GENERIC NUCLEIC ACIDS.






FIG. 5




FIG. 6




FIG. 7

INTERNATIONAL SEARCH REPORT

Int .ional Application No
PCT/GB 98/00130

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 04160 A (ISIS INNOVATION ; SOUTHERN EDWIN (GB); CUMMINS WILLIAM JONATHAN (GB)) 9 February 1995 see the whole document ---	1-20
X	WO 95 20053 A (MEDICAL RES COUNCIL ; SIBSON DAVID ROSS (GB)) 27 July 1995 cited in the application see page 23 - page 27; claims 9-13, 24-26, 28, 29; figure 2; examples 3, 4 ---	1-5, 7-11, 13-16, 18, 20
X	WO 96 33205 A (SPECTRAGEN INC) 24 October 1996 cited in the application see the whole document ---	1-5, 7-11, 13-16, 18, 20
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "Z" document member of the same patent family

Date of the actual completion of the international search

8 May 1998

Date of mailing of the international search report

18/05/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Molina Galan, E

INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/GB 98/00130

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 09248 A (ARCH DEV CORP ;DRMANAC RADOJE (US)) 6 April 1995 ----	
A	WO 89 11211 A (BIOTECHNOLOG FORSCHUNG GMBH) 30 November 1989 -----	

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int .ional Application No

PCT/GB 98/00130

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9504160 A	09-02-95	AT 159767 T	15-11-97
		AU 7269194 A	28-02-95
		CA 2168010 A	09-02-95
		CN 1131440 A	18-09-96
		DE 69406544 D	04-12-97
		DE 69406544 T	26-02-98
		EP 0711362 A	15-05-96
		EP 0778280 A	11-06-97
		ES 2108479 T	16-12-97
		FI 960403 A	29-01-96
		HU 73802 A	30-09-96
		JP 9501830 T	25-02-97
		NO 960370 A	28-03-96
WO 9520053 A	27-07-95	AU 1459595 A	08-08-95
		EP 0739422 A	30-10-96
		JP 9508268 T	26-08-97
WO 9633205 A	24-10-96	AU 5549096 A	07-11-96
WO 9509248 A	06-04-95	AU 8072794 A	18-04-95
		BR 9407712 A	12-02-97
		CA 2172722 A	06-04-95
		CN 1136330 A	20-11-96
		CZ 9600905 A	16-10-96
		EP 0723598 A	31-07-96
		FI 961283 A	22-05-96
		HU 75993 A	28-05-97
		JP 9505729 T	10-06-97
		NO 961165 A	23-05-96
		NZ 275194 A	22-09-97
		PL 313735 A	22-07-96
WO 8911211 A	30-11-89	DE 58908694 D	12-01-95
		EP 0377015 A	11-07-90
		JP 3502641 T	20-06-91
		US 5114839 A	19-05-92